Spots Global Cancer Trial Database for Monotherapy With Eribulin In Her2 Negative Metastatic Breast Cancer as a First Line Treatment
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Monotherapy With Eribulin In Her2 Negative Metastatic Breast Cancer as a First Line Treatment
Official Title: A Phase IIa Prospective, Multicenter, Open and Not Controlled of the Efficacy and Tolerability on the First Line Treatment With Eribulin as a Unic Agent on Patients With HER2 Negative Metastatic Breast Cancer Previously Treated With Taxanes
Study ID: NCT02061085
Interventions
Study Description
Brief Summary: Multicentre, prospective, non-controlled phase II clinical trial to evaluate the efficacy and tolerability of first line single agent Eribulin in patients with HER2-negative metastatic breast carcinoma previously exposed to taxanes for early stage. The primary objective of the study is to determine the median time to progression achieved with Eribulin. Other secondary objectives will be; overall response rate, clinical benefit rate, time to treatment progression, duration of response and toxicity profile.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
, Zaragoza, Aragón, Spain
, Oviedo, Asturias, Spain
, Salamanca, Castilla Y León, Spain
, Barcelona, Cataluña, Spain
, Badajoz, Extremadura, Spain
, La Coruña, Galicia, Spain
, Palma de Mallorca, Illes Balears, Spain
, Gran Canaria, Islas Canarias, Spain
, Pamplona, Navarra, Spain
, Madrid, , Spain
, Valencia, , Spain
Contact Details
Name: Antonio Llombart, MD
Affiliation: Valencia
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
